NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
NeoGenomics was founded in 2001 by a group of oncologists, pathologists, and entrepreneurs with a passion for improving patient care through improved molecular diagnostics. Initially, NeoGenomics prepared and interpreted a variety of clinical testing including cytogenetics, disomy analyses, FISH, and CGH arrays. After years of investing in inventory, infrastructure and personnel, the company has become a full-service provider of clinical laboratory services for pathologists, oncologists, urologists and other clinical authorities.
We save lives by improving patient care.
By providing uncompromising quality, exceptional service and
innovative solutions, we will be the world’s leading cancer testing and information company.
Mr. Jeffrey S. Sherman M.B.A. (Chief Financial Officer)
Mr. Hutan Hashemi J.D. (Chief Compliance Officer)
Ms. Cynthia J. Dieter (Chief Accounting Officer)
Ms. Ali Olivio (Gen. Counsel & Corp. Sec.)
Mr. John Mooney (Chief Technology Officer)
Dr. Shashikant Kulkarni Facmg, M.B.A., M.S., Ph.D. (Pres of Lab Operations & Chief Scientific Officer)
Charlie Eidson (Director of Investor Relations and Corp. Devel.)
Recognition and Awards
NeoGenomics has been named one of the Top 100 Fastest Growing Companies by Inc. Magazine and one of the Top 10 Fastest Growing Companies in Healthcare by Deloitte.